低剂量沙库巴曲缬沙坦治疗老年射血分数降低型慢性心力衰竭的效果及安全性

Abstract
Figure/Table
References (22)
Related Citation (15)

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To evaluate the therapeutic effect and safety of low-dose Sacubitril Valsartan in treatment of heart failure with reduced ejection fraction (HFrEF) in the elderly patients. Methods A total of 82 elderly patients with HFrEF (age≥60 years old) treated in Department of Cardiology of Shanghai East Hospital Ji′an Hospital from April 2019 to March 2021 were selected as research objects. They were divided into study group (n=42) and control group(n=40) according to coin toss method. The control group was treated with routine anti chronic heart failare method, the study group treated with Sacubitril Valsarta after stopping using angiotensin converting enzyme inhibitor (ACEI) in routine treatment. The 6 minutes walking test (6-MWT), plasma N-terminal pro-B-type natriuretic peptide (NTproBNP) and cardiac ultrasound were determined before and after 6 months of treatment to detect the patients′ cardiac function. The changes of cardiac function grade indexes in the two groups were evaluated, and the treatment effect and drug safety of the two groups were analyzed. Results There were no statistically significances in plasma NT-proBNP,left ventricle ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD), left atrial diameter (LA),systolic blood pressure (SBP), diastolic blood pressure (DBP), heart rate (HR), 6-MWT levels between two groups before treatment (P＞0.05). After 6 months of treatment, plasma NT-proBNP, LVEDD, LA, SBP, DBP, HR in study group were lower than those in control group, while the levels of LVEF and 6-MWT in study group were higher than those in control group, the differences were statistically significant (P＜0.05). The total effective rate of the study group was higher than that of the control group, the difference was statistically significant (P＜0.05). While there was no significant difference in total incidence of adverse reactions between the two groups (P＞0.05). Conclusion Low-dose Sacubitril Valsartan can effectively inhibit the ventricular remodeling of elderly HFrEF patients, as well improve clinical symptoms and exercise endurance in elderly HFrEF patients with good safety.

Key words： Sacubitril Valsartan Chronic heart failure;Elderly Therapeutic effect Safety

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LIU Yuansheng
	ZHOU Hua
	LIU Zhongwen
	LIAO Bin
	LIU Lingjuan
	OU Junping▲

Cite this article:

LIU Yuansheng,ZHOU Hua,LIU Zhongwen, et al. Efficacy and safety of low-dose Sacubitril Valsartan in treatment of heart failure with reduced ejection fraction in the elderly[J]. 中国当代医药, 2022, 29(16): 20-24.

URL:

https://www.dangdaiyiyao.com/EN/ OR https://www.dangdaiyiyao.com/EN/Y2022/V29/I16/20

[1]	ZhangY，Zhang J，Butle J，et al.Contemporary Epidemiology，Management and Outcomes of Patients hospitalized for heart failure in china：Results From the China Heart Failure（China-HF）Registy[J].J Card Fail，2017，23（12）：868-875.
[2]	王华，梁延春.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志，2018，46（10）：760-789.
[3]	崔晓通，周京敏，葛均波.PARADIGM-HF 研究结果解读[J].中国循环杂志，2018，33（2）：203-205.
[4]	Beltrán P，Palau P，Domíneguez E，et al.Sacubitril/valsartan and shorterm changes in the 6-minute walk test：A pilot study[J].Int J Cardiol，2018，252：136-139.
[6]	中华医学会老年医学分会心血管疾病学组，《老年慢性心力衰竭诊治中国专家共识》编写组.老年人慢性心力衰竭诊治中国专家共识（2021）[J].中华老年医学杂志，2021，40（5）：550-561.
[8]	胡大清，王娓，张楠.诺欣妥治疗充血性心力衰竭847 例临床疗效真实世界分析[J].中国医药指南，2020，18（2）：90-91.
[9]	乔香瑞，刘军辉，花蕊，等.循环单核细胞和血浆中GDF-15 和NT-proBNP 对慢性心力衰竭的诊断及心血管事件的预测价值（英文）[J].南方医科大学学报，2019，39（11）：1273-1279.
[5]	McDonagh TA，Metra M，Adamo M，et al.2021 ESC Guidelines for the diagnosis and treatment of acut and chronic heart failure[J].Eur Heart J，2021，42（36）：3599-3726.
[7]	Desai AS，Solomon SD，Shah AM，et al.Effect of Sacubitril-Valsartan vs Enalapril on Aortic Stiffness in Patients With Heart Failure and Reduced Ejection Fraction：A Randomized Clinical Trial[J].JAMA，2019，322（11）：1077-1084.
[10]	Linssen GCM，Jaarsma T，Hillege HL，et al.A comparison of the prognostic value of BNP versus NT-proBNP after hospitalization for heart failure[J].Neth Heart J，2018，26（10）：486-492.
[11]	周文杰，谢仁兵，罗正义.沙库巴曲/缬沙坦联合曲美他嗪对急诊经皮冠状动脉介入术后患者心功能的影响[J].中国医药科学，2021，11（13）：80-83.
[12]	刘伟，魏恒.沙库巴曲缬沙坦钠片治疗冠心病合并慢性心力衰竭的临床效果[J].中国当代医药，2022，29（1）：68-71.
[13]	Campbeli DJ.Long-term neprilysin inhibition-implication for ANRIs[J].Nat Rev Cardiol，2017，14（3）：171-186.
[14]	Rodil Fraile R，Malafarina V，Tiberio López G.Sacubitrilvalsartan in heart failure and multimorbidity patients[J].Esc Heart Fail，2018，5（5）：956-959.
[15]	姜阳，董鹏，刘芳，等.沙库巴曲缬沙坦治疗慢性心力衰竭的有效性及安全性研究[J].中国分子心脏病学杂志，2020，20（2）：3297-3300.
[16]	Bodnar RJ.Endogenous opiates and behavior：2019[J].Peptides，2021，114：170547.
[17]	Pilozzi A，Carro C，Huang X.Roles of β-Endorphin in Stress，Behavior，Neuroinflammation，and Brain En ergy Metabolism[J].Int J Mol Sci，2020，22（1）：338.
[18]	Maslov MY，Foianini S，Orlov MV，et al.A Novel Paradigm for Sacubitril/Valsartan：Beta-Endorphin Elevation as a Contributor to Exercise Tolerance Improvement in Rats With Preexisting Heart Failure Induced by Pressure Overload[J].J Card Fail，2018，24（11）：773-782.
[19]	Greene SJ，Fonarow GC，Vaduganathan M，et al.The vulnerable phase after hospitalization for heart failure[J].Nat Rev Cardiol，2015，12（4）：220-229.
[20]	周京敏，徐亚妹.心力衰竭易损期的心率管理：概念与策略[J].心电与循环，2018，37（2）：80-82.
[21]	Logeart D，Isnard R，Resche-Rigon M，et al.Heart Failure of the French Society of Cardiology. Current aspect of the spectrum of acute heart failure syndrome in a real-life setting：the OFICA study[J].Eur J Heart Fail，2013，15（4）：465-476.
[22]	沈国英，金智敏，赵晓薇，等.老年心力衰竭患者出院时血压水平与预后的关系[J].中华老年心血管病杂志，2015，17（2）：125-129.